10-Q: Beyond Air Reports Q2 2026 Results, Faces Funding Needs

Beyond Air, Inc. filed its Q2 2026 10-Q, detailing continued operational losses and a focus on securing future funding, alongside progress in its medical device and biopharmaceutical segments.

Summary

• Beyond Air, Inc. reported its financial results for the quarter ended June 30, 2026.
• The company experienced a net loss of $8.15 million for the quarter, compared to $8.08 million in the prior year period.
• Revenues remained stable at $1.77 million for the quarter, consistent with the prior year.
• Operating expenses decreased to $6.84 million from $7.77 million in the prior year, primarily due to reduced research and development spending.
• The company had cash, cash equivalents, and marketable securities totaling $9.8 million as of June 30, 2026, with an additional $5.4 million in restricted cash.
• Management believes substantial doubt exists about the company's ability to continue as a going concern and anticipates requiring additional funding within one year.
• A 1-for-20 reverse stock split was completed on July 13, 2026, to regain compliance with Nasdaq's minimum bid price requirement.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued net losses, significant cash burn, and the ongoing need for additional funding, despite some positive developments in product development and regulatory progress.

Positives

• Revenues remained stable at $1.77 million for the quarter, indicating consistent commercial activity.
• Research and development expenses decreased to $2.0 million from $3.1 million in the prior year, suggesting improved cost management in this area.
• The company regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split.
• The company's majority-owned affiliate, NeuroNos, raised $2.0 million in a private placement, with an additional $3.9 million raised subsequently.
• The LungFit PH II PMA supplement was submitted to the FDA in June 2025, aiming to expand the product's market reach.
• The company received regulatory approvals in over 27 countries outside the US and EU for LungFit PH and signed distribution agreements covering over 40 countries.

Negatives

• The company reported a net loss of $8.15 million for the quarter, with an accumulated deficit of $327.5 million.
• Cash, cash equivalents, and marketable securities stood at $9.8 million, with significant cash outflows from operations ($4.9 million for the quarter).
• Management concluded that the company will require additional funding within one year, raising substantial doubt about its ability to meet obligations.
• Interest and finance expenses increased significantly to $1.49 million from $0.55 million in the prior year, driven by increased outstanding debt.
• The company's common stock was previously non-compliant with Nasdaq's minimum bid price requirement, necessitating a reverse stock split.
• The company's ability to continue operating beyond the first fiscal quarter of 2028 is dependent on successful commercialization and further funding.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt, requiring significant additional funding within one year.
• Failure to maintain compliance with Nasdaq's continued listing standards could result in delisting, adversely affecting liquidity and stock price.
• The company is dependent on third-party suppliers, with approximately 90% of materials purchased from one vendor in the current quarter.
• Regulatory approvals for product candidates in foreign jurisdictions are not assured and delays could materially impact operations.
• The company faces risks associated with the development and commercialization of new products, including market acceptance and competition.
• The company's future capital needs are substantial and financing may not be available on acceptable terms, or at all.

Future Outlook

The company expects to incur net losses and significant cash outflows for at least the next year, requiring additional funding. Future capital needs depend on the success of commercialization, clinical trials, regulatory approvals, and potential collaborations or licensing agreements. The company's ability to continue operating beyond the first fiscal quarter of 2028 is contingent on the successful commercial launch of LungFit PH, obtaining international partners, and potentially raising additional funds.

Management Comments

• Management believes that the company will require additional funding within one year from the date these unaudited condensed consolidated financial statements are issued.
• Management is confident that the efforts to arrange financing, while not assured, will enable the Company to meet its obligations.
• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Industry Context

StockSavvy.ai notes that Beyond Air operates in the competitive medical device and biopharmaceutical sector, focusing on nitric oxide-based therapies. The company's progress with LungFit PH for PPHN and its expansion into other indications like viral lung infections and NTM, as well as its oncology and neurology programs, are key differentiators. However, the sector is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles, which are reflected in Beyond Air's financial performance and ongoing need for capital.

Comparison to Industry Standards

• The company's revenue of $1.77 million for the quarter is modest compared to established medical device companies, reflecting its commercial-stage but still developing market penetration.
• The net loss of $8.15 million for the quarter is substantial, typical for companies investing heavily in R&D and clinical trials in the biopharmaceutical sector, but the continued losses and need for funding are a concern.
• The company's focus on nitric oxide delivery systems for various respiratory and other conditions aligns with a growing interest in novel therapeutic approaches, but direct competitors in specific niches may exist.
• The company's reliance on third-party suppliers for critical materials, with 90% from a single vendor, is a potential risk not uncommon in specialized manufacturing but highlights a vulnerability.
• The company's efforts to secure regulatory approvals in multiple international markets (over 27 countries outside US/EU) are standard practice for global medical device companies aiming for broad market access.

Legal Proceedings

• No legal proceedings are currently expected to have a material effect on the company's financial position, cash flows, or results of operations.

Related Party Transactions

• On November 1, 2024, the Company entered into a Loan and Security Agreement for a secured loan with certain lenders, including its former Chief Executive Officer Steven Lisi and director Robert Carey.
• On June 2, 2025, the Company received $2.0 million of advanced financing from a related party, director Robert Carey, who is also an existing lender under its Loan Agreement.
• The company's Chief Executive Officer and Chief Financial Officer participated in a private placement of shares and warrants on July 29, 2026, purchasing an aggregate of 39,062 shares and accompanying warrants for approximately $0.2 million.

Stakeholder Impact

• Shareholders may experience continued dilution if the company needs to raise additional equity financing.
• The company's ability to meet its obligations and continue operations impacts creditors and suppliers.
• The ongoing development of medical devices and therapies has the potential to positively impact patients and healthcare providers.
• Employees' job security may be affected by the company's need for additional funding and its ability to achieve commercial success.

Next Steps

• Continue commercialization efforts for LungFit PH in the United States.
• Pursue regulatory approvals and market expansion in over 40 countries outside the United States.
• Advance the LungFit PH II PMA supplement submission to the FDA.
• Continue discussions with the FDA in calendar 2026 regarding the path forward for the NTM program.
• Seek additional financing to support ongoing operations, R&D, and commercialization efforts.
• Initiate Phase 1b trial for UNO therapy pending future funding.

Key Dates

Recommendation

The company's continued net losses, substantial cash burn, and reliance on future financing create significant uncertainty. While there are positive developments in product pipelines and regulatory progress, the immediate financial health and going concern issues warrant a cautious 'hold' stance until a clearer path to profitability and sustainable funding is established.

Keywords

Beyond Air, LungFit PH, Nitric Oxide, Medical Device, Biopharmaceutical, PPHN, Form 10-Q, Quarterly Report